Aubilic acid (OCA) is a semi-synthetic analog of bile acid chenodeoxycholic acid, which is capable of selectively activating bile acid receptor FXR. Preclinical and clinical studies suggest that OCA has a good anti-cholestasis, anti-inflammatory and anti-fibrosis effects.
To assess the safety and efficacy of OCA for the treatment of poorly treated patients with UDCA, Dr. Hirschfield, MD, of the University of Birmingham, UK, completed a study suggesting that OCA was used in the treatment of UDCA poorly responded to PBC Patient treatment is effective and published on the latest Gastroenterology.
This was a randomized, double-blind, controlled trial of 165 patients with PBC (95% female) who had been diagnosed and treated with UDCA for more than 6 months. The ALP level was 1.5-10 times before the trial was normal. Subjects were randomly divided into four groups, three OCA treatment groups were 10 mg group, 25 mg group and 50 mg group, and the placebo group, the daily Dayton time is 3 months, the whole process of all subjects continue take a conventional therapeutic dose of UDCA.
82% of the subjects completed the trial results showed that the OCA treatment group was significantly better than the placebo group in the control group by recording changes and safety assessment before and after blood biochemical treatment such as ALP.
The results showed that OCA treatment group significantly reduced ALP levels in subjects (P <0.0001, Figure 1), OCA treatment group ALP levels compared with the average before treatment decreased by 21% -25%, while the placebo group only fell by 3%. 69% (68/99) of the OCA treatment group, the level of ALP decreased by more than 20%, while the placebo group only 8%.